Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

Jeffrey L. Dage, Alexandra M V Wennberg, David C. Airey, Clinton E. Hagen, David S Knopman, Mary Margaret Machulda, Rosebud O Roberts, Clifford R Jr. Jack, Ronald Carl Petersen, Michelle M Mielke

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Introduction Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)–related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. Methods Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1 tau assay. Results Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = −0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). Discussion Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.

Original languageEnglish (US)
Pages (from-to)1226-1234
Number of pages9
JournalAlzheimer's and Dementia
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

tau Proteins
Cognition
Population
Positron-Emission Tomography
Alzheimer Disease
Magnetic Resonance Imaging
Amyloid
Neuroimaging
Longitudinal Studies
Odds Ratio
Education

Keywords

  • Amyloid
  • Cognition
  • Cortical thickness
  • MCI
  • Memory
  • MRI
  • Plasma tau

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. / Dage, Jeffrey L.; Wennberg, Alexandra M V; Airey, David C.; Hagen, Clinton E.; Knopman, David S; Machulda, Mary Margaret; Roberts, Rosebud O; Jack, Clifford R Jr.; Petersen, Ronald Carl; Mielke, Michelle M.

In: Alzheimer's and Dementia, Vol. 12, No. 12, 01.12.2016, p. 1226-1234.

Research output: Contribution to journalArticle

@article{41e63bc5817b4fbda0ecc51d8abd6c10,
title = "Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort",
abstract = "Introduction Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)–related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. Methods Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1 tau assay. Results Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = −0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). Discussion Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.",
keywords = "Amyloid, Cognition, Cortical thickness, MCI, Memory, MRI, Plasma tau",
author = "Dage, {Jeffrey L.} and Wennberg, {Alexandra M V} and Airey, {David C.} and Hagen, {Clinton E.} and Knopman, {David S} and Machulda, {Mary Margaret} and Roberts, {Rosebud O} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl} and Mielke, {Michelle M}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jalz.2016.06.001",
language = "English (US)",
volume = "12",
pages = "1226--1234",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

AU - Dage, Jeffrey L.

AU - Wennberg, Alexandra M V

AU - Airey, David C.

AU - Hagen, Clinton E.

AU - Knopman, David S

AU - Machulda, Mary Margaret

AU - Roberts, Rosebud O

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

AU - Mielke, Michelle M

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)–related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. Methods Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1 tau assay. Results Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = −0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). Discussion Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.

AB - Introduction Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)–related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. Methods Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1 tau assay. Results Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = −0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). Discussion Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.

KW - Amyloid

KW - Cognition

KW - Cortical thickness

KW - MCI

KW - Memory

KW - MRI

KW - Plasma tau

UR - http://www.scopus.com/inward/record.url?scp=84996798698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996798698&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.06.001

DO - 10.1016/j.jalz.2016.06.001

M3 - Article

C2 - 27436677

AN - SCOPUS:84996798698

VL - 12

SP - 1226

EP - 1234

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 12

ER -